GlassScriptPhysician profile
Heather Chasteen
NPI 1487225280
$5,047.73
in general payments reported to CMS, 2019-2025
19 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $403 · 2022: $1,809 · 2023: $1,647 · 2024: $955 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.15 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $853.47 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $752.46 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $434.97 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $354.17 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $268.83 | 2023-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $252.04 | 2022-2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $198.47 | 2021-2024 | Jornay Pm |
| Almatica Pharma LLC | $163.10 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $155.88 | 2023 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $136.91 | 2021-2024 | Nuedexta, Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $133.69 | 2022-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $124.95 | 2022 | |
| Sunovion Pharmaceuticals INC. | $102.28 | 2021-2022 | |
| Alkermes, INC. | $75.50 | 2022-2024 | Aristada, Vivitrol, Lybalvi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $60.34 | 2022-2024 | Rexulti |
| Corium, LLC | $51.67 | 2022-2023 | Azstarys |
| Noven Therapeutics, LLC | $17.81 | 2024 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $13.04 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Chasteen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.